SR One Capital Management LP Takes $6.14 Million Position in Oculis Holding AG $OCS

Key Points

• SR One Capital Management LP has purchased 322,500 shares of Oculis Holding AG (NASDAQ:OCS), valued at approximately $6.14 million, making it the firm's 8th largest position.
• Chardan Capital has increased its price target for Oculis from $28.00 to $33.00, maintaining a "buy" rating as of May 9th.
• Oculis is currently trading around $17.90 with a market capitalization of $781.51 million and a price-to-earnings ratio of -6.78.

SR One Capital Management LP bought a new position in Oculis Holding AG (NASDAQ:OCS - Free Report) in the first quarter, according to its most recent disclosure with the SEC. The firm bought 322,500 shares of the company's stock, valued at approximately $6,137,000. Oculis comprises approximately 1.6% of SR One Capital Management LP's portfolio, making the stock its 8th biggest position. SR One Capital Management LP owned about 0.74% of Oculis as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Bellevue Group AG purchased a new position in shares of Oculis during the 4th quarter worth $170,000. XTX Topco Ltd acquired a new stake in shares of Oculis during the 4th quarter worth about $225,000. Kestra Private Wealth Services LLC acquired a new stake in shares of Oculis during the 1st quarter worth about $234,000. Geode Capital Management LLC raised its position in shares of Oculis by 12.0% during the 4th quarter. Geode Capital Management LLC now owns 16,744 shares of the company's stock worth $284,000 after acquiring an additional 1,800 shares in the last quarter. Finally, Citadel Advisors LLC acquired a new stake in shares of Oculis during the 4th quarter worth about $389,000. 22.30% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

OCS has been the topic of several research analyst reports. HC Wainwright lifted their price target on Oculis from $32.00 to $33.00 and gave the stock a "buy" rating in a research report on Friday. Chardan Capital lifted their target price on Oculis from $28.00 to $33.00 and gave the company a "buy" rating in a research note on Friday, May 9th. Three analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $35.67.

Oculis Trading Up 0.9%

NASDAQ OCS traded up $0.16 during trading on Friday, hitting $17.96. 13,805 shares of the company traded hands, compared to its average volume of 44,464. Oculis Holding AG has a 12 month low of $11.56 and a 12 month high of $23.08. The business has a fifty day simple moving average of $18.41 and a 200 day simple moving average of $18.74. The company has a market capitalization of $784.13 million, a P/E ratio of -6.80 and a beta of 0.27.

Oculis (NASDAQ:OCS - Get Free Report) last posted its earnings results on Thursday, August 21st. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.06). Oculis had a negative net margin of 13,788.70% and a negative return on equity of 92.95%. The company had revenue of $0.25 million for the quarter, compared to the consensus estimate of $0.14 million. Equities research analysts predict that Oculis Holding AG will post -2.09 EPS for the current fiscal year.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.